Lncrna FGFR3-AS1 Is a Prognostic Indicator for Ovarian Cancer and Induces Cell Proliferation and Hinders Apoptosis
Abstract
Background: Ovarian cancer is one of the most common malignant tumors in Gynecology, whose treatment was seriously limited by the unclear understanding of molecular mechanism in disease development. LncRNA FGFR3-AS1 is involved in human cancers. In this study, we aimed to clarify its regulatory effect on ovarian cancer.
Methods: Ovarian cell model was used in 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazoliumbromide (MTT) assay and flow cytometry for investigating the role of LncRNA FGFR3-AS1 in ovarian cancer. Western blot detection (CCND1、CDK6、MAPK9 and PIK3CA) tumor regulatory proteins. The study was conducted between March 2020 and October 2022 at General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, China.
Results: The results demonstrated the upregulation of LncRNA FGFR3-AS1 in ovarian cancer, whose expression was positively related to tumor grade and AJCC stage, and negatively correlated with patients’ prognosis. LncRNA FGFR3-AS1 promoted ovarian cancer development through promoting cell growth and inhibiting cell apoptosis. PI3K signaling pathway-related proteins may be implicated in the LncRNA FGFR3-AS1 induced regulation of ovarian cancer.
Conclusion: LncRNA FGFR3-AS1 was involved in the development of ovarian cancer, which has the potential to become therapeutic target and prognostic indicator in ovarian cancer treatment.
2. Stewart C, Ralyea C, Lockwood S (2019). Ovarian cancer: an integrated review. Semin Oncol Nurs, 35(2):151-156.
3. Narod S (2016). Can advanced-stage ovari-an cancer be cured? Nat Rev Clin Oncol, 13(4):255-261.
4. Grunewald T, Ledermann JA (2017). Tar-geted therapies for ovarian cancer. Best Pract Res Clin Obstet, 41:139-152.
5. Guan L, Lu Y (2018). New developments in molecular targeted therapy of ovarian cancer. Discov Med, 26(144):219-229.
6. Lim HJ, Ledger W (2016). Targeted therapy in ovarian cancer. Womens Health, 12(3):363-378.
7. Sun J, Wang X, Fu C, Wang X, Zou J, Hua H, Bi Z (2016). Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural an-tisense transcript FGFR3. Mol Biol Rep, 43(5):427-36.
8. Liao X, Chen J, Liu Y, et al (2018). Knock-down of long noncoding RNA FGFR3- AS1 induces cell proliferation inhibi-tion, apoptosis and motility reduction in bladder cancer. Cancer Biomark, 21 (2):277-285.
9. Blanca A, Requena MJ, Alvarez J, et al (2016). FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recur-rence. Biomark Med, 10(3):243-253.
10. Chen T, Xie W, Xie L, et al (2015). Expres-sion of long noncoding RNA lncRNA- n336928 is correlated with tumor stage and grade and over- all survival in blad-der cancer. Biochem Biophys Res Commun, 468(4):666-70.
11. Pandith AA, Shah ZA, Siddiqi MA (2013). Oncogenic role of fifibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol, 31(4):398-406.
12. Zhang Y, Huang K, Cai H, Chen S, Sun D, Jiang P (2020). The role of nucleolar spindle-associated protein 1 in human ovarian cancer. J Cell Biochem, 121(11):4397-4405.
13. Gao S, Bian T, Zhang Y, Su M, Liu Y (2019). TCF12 overexpression as a poor prog-nostic factor in ovarian cancer. Pathol Res Pract, 215(9):152527.
14. Zhang J, Liu XH, Li C, et al (2020). SNCG promotes the progression and metasta-sis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway. J Exp Clin Canc Res, 39(1):79.
| Files | ||
| Issue | Vol 52 No 11 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i11.14040 | |
| Keywords | ||
| Ovarian cancer Prognosis Cell proliferation Cell apoptosis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
